2025-09-14 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co. (LLY) based on the data you provided, formatted as requested.

**Report on Eli Lilly and Co. (LLY)**

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** LLY
*   **Company Overview:** Eli Lilly and Co. is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.
*   **LLY Cumulative Return:** 217.84%
*   **VOO Cumulative Return:** 89.18%
*   **Absolute Divergence (LLY - VOO):** 128.66%
*   **Divergence Range:** Max: 1095.9, Min: -23.1, Current: 754.0
*   **Relative Divergence:** 69.4 (This indicates the current divergence is at the 69.4th percentile of its historical range, suggesting LLY is significantly outperforming VOO relative to its past performance.)

**Alpha, Beta Analysis Table & Interpretation**

| Year      | CAGR    | MDD     | Alpha   | Beta    | Cap(B) |
| :---------- | :------ | :------ | :------ | :------ | :------- |
| 2015-2017 | 1.0%    | 0.0%    | -2.0%   | -0.1    | 75.7    |
| 2016-2018 | 27.0%   | 58.6%   | 32.0%   | 0.0     | 103.7   |
| 2017-2019 | 41.0%   | 58.6%   | 18.0%   | 0.0     | 117.8   |
| 2018-2020 | 53.0%   | 58.6%   | 26.0%   | 0.0     | 151.4   |
| 2019-2021 | 104.0%  | 60.6%   | 55.0%   | 0.0     | 247.6   |
| 2020-2022 | 96.0%   | 65.0%   | 89.0%   | 0.1     | 328.0   |
| 2021-2023 | 129.0%  | 65.0%   | 109.0%  | 0.2     | 522.6   |
| 2022-2024 | 145.0%  | 72.0%   | 119.0%  | 0.2     | 692.1   |
| 2023-2025 | 81.0%   | 76.8%   | 26.0%   | 0.2     | 677.2   |

**Analysis:**

*   **CAGR:** The Compounded Annual Growth Rate demonstrates significant growth acceleration, especially in recent years.
*   **MDD:** The Maximum Drawdown indicates substantial volatility, especially in the 2022-2025 window.
*   **Alpha:** Consistently positive and high Alpha values indicate strong outperformance relative to the market, suggesting that LLY's returns are not simply due to market movements.
*   **Beta:** Low Beta values suggest LLY's price is not as sensitive to market movements, which is a plus.
*   **Cap(B):** Market capitalization has seen substantial growth over the years.

**2. Recent Stock Price Movement**

*   **Current Price:** 755.39
*   **Last Market Data:** Price: 755.39, Previous Close: 756.28, Change: -0.12
*   **5-Day Moving Average:** 751.108
*   **20-Day Moving Average:** 727.9
*   **60-Day Moving Average:** 748.4085

**Analysis:** The stock price is slightly down from the previous close. The price is above the 5-day, 20-day, and 60-day moving averages, which generally indicates an upward trend.  The 5-day moving average is above the 60-day moving average, but the 20-day is lower than the 60-day, suggesting possible consolidation or a short-term pullback within the broader uptrend.

**3. Indicators & Expected Return**

*   **Market Risk Indicator (MRI):** 0.3233 (Low Risk)
*   **RSI:** 68.56 (Approaching overbought territory, but not yet definitively so)
*   **PPO:** 0.7604 (Positive, indicating an uptrend, but needs more context for a complete interpretation)
*   **Hybrid Signal:**  cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-09-02). This suggests a buying opportunity, but with caution due to the market risk.
*   **Recent (20-day) Relative Divergence Change:** 1.5 (+) indicating short-term upward momentum.
*   **Price Change Note:** The change of -0.12 is not significant enough to indicate a major event.
*   **Expected Return:** 301.6% (Long-term projected outperformance vs. S&P 500, assuming dollar-cost averaging).

**4. Recent News & Significant Events**

*   **Bullish Sentiment:** Several articles from Motley Fool highlight LLY as a potential "monster stock" for long-term holding and a solid dividend stock.
*   **Alzheimer's Awareness Campaign:** Eli Lilly's "Brain Health Matters" campaign increases public awareness and strengthens the company's brand image.
*   **AI Drug Platform & Oncology Breakthroughs:** The launch of the AI drug platform and oncology breakthroughs could positively impact investor sentiment, as noted by Simply Wall St.
*   **Morningstar Coverage:** Indicates ongoing analyst attention.

**5. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.68 (~Buy)
*   **Opinions:** 26
*   **Target Price:** Avg: 891.62 / High: 1190.00 / Low: 650.00
*   **Recent Rating Changes:** No recent changes provided.
**Analysis:** Analyst consensus is strongly positive, with a "Buy" rating and a significant average target price well above the current price. This suggests analysts believe the stock has considerable upside potential.

**6. Earnings Analysis**

| 날짜       | EPS   | 매출       |
| :--------- | :---- | :--------- |
| 2025-08-07 | 6.3   | 15.56 B$   |
| 2025-05-01 | 3.07  | 12.73 B$   |
| 2024-10-30 | 1.08  | 11.44 B$   |
| 2024-08-08 | 3.29  | 11.30 B$   |
| 2025-08-07 | 3.29  | 11.30 B$   |

**Analysis:**
*   The most recent EPS ($6.3) and revenue ($15.56B) show substantial growth compared to previous quarters. This indicates strong financial performance.

**7. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue      | Profit Margin |
| :----------- | :----------- | :------------ |
| 2025-06-30 | $15.56B     | 84.27%        |
| 2025-03-31 | $12.73B     | 82.53%        |
| 2024-12-31 | $13.53B     | 82.24%        |
| 2024-09-30 | $11.44B     | 81.02%        |
| 2024-06-30 | $11.30B     | 80.80%        |

**Capital and Profitability:**

| Quarter      | Equity      | ROE      |
| :----------- | :---------- | :------- |
| 2025-06-30 | $18.27B    | 30.98%  |
| 2025-03-31 | $15.76B    | 17.50%  |
| 2024-12-31 | $14.19B    | 31.07%  |
| 2024-09-30 | $14.24B    | 6.81%   |
| 2024-06-30 | $13.56B    | 21.88%  |

**Analysis:**
*   **Revenue and Profitability:** Revenue and profit margins have been consistently increasing, indicating improved operational efficiency and strong demand for LLY's products. The latest profit margin of 84.27% is exceptionally high.
*   **Capital and Profitability:** Equity has grown steadily. ROE fluctuates but remains generally strong, reflecting effective utilization of equity to generate profits.

**8. 종합 Analysis**

Eli Lilly (LLY) presents a compelling investment case based on the provided data:

*   **Outperformance:**  LLY has significantly outperformed the S&P 500 (VOO), and the relative divergence suggests continued strength.
*   **Strong Financials:** Recent earnings, revenue, and profit margin data show substantial growth. High ROE indicates efficient capital utilization.
*   **Positive Outlook:** Analyst consensus is strongly positive, with a buy rating and a substantial average target price.
*   **Innovation & Awareness:** AI drug platform launch, oncology breakthroughs, and Alzheimer's awareness campaign contribute to a positive outlook.
*   **Technicals:** The current price is above key moving averages, indicating an uptrend, although the RSI suggests it may be approaching overbought conditions.
*   **Risk:** The MDD of 76.8% suggests some volatility.
*   **Investment Strategy:** The Hybrid signal recommends a moderate investment strategy, and the projected long-term outperformance of 301.6% suggests strong potential returns with dollar-cost averaging.
